Harrow Health, Inc. Soared

Tue, Sep 27, 2022 at 07:33 PM

Harrow Health, Inc. (HROW:NASDAQ) rocketted at $9.73, representing a gain of 27.9%. On Tue, Sep 27, 2022, HROW:NASDAQ hit a New 2-Week High of $9.73. The stock appeared on our News Catalysts scanner on Tue, Sep 27, 2022 at 02:44 PM in the 'BIOTECH' category. From Tue, Sep 13, 2022, the stock recorded 20.00% Up Days and 36.36% Green Days

About Harrow Health, Inc. (HROW:NASDAQ)

Imprimis Pharmaceuticals Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.

Top 10 Gainers:

Avenue Therapeutics, Inc. (ATXI:NASDAQ), 106.25%
Scienjoy Holding Corporation (SJ:NASDAQ), 47.9%
Sonendo Inc. (SONX:NYSE), 42.74%
X4 Pharmaceuticals, Inc. (XFOR:NASDAQ), 40.18%
Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 37.46%
Grove Collaborative Holdings Inc. Class A (GROV:NYSE), 35.47%
InMed Pharmaceuticals Inc. (INM:NASDAQ), 31.31%
AN2 Therapeutics Inc. (ANTX:NASDAQ), 31.13%
Intelligent Living Application Group Inc. (ILAG:NASDAQ), 28.43%
Harrow Health, Inc. (HROW:NASDAQ), 27.86%